Showing results (361-370 of 374) with videos related to
Sort By:
Pageof 38
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025Gregory J Riely, Douglas E Wood, Dara L Aisner, et al.JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2026
Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyGregory J Riely, Douglas E Wood, Dara L Aisner, et al.Blood|December 8, 2025
Immune thrombocytopenia in patients treated with immune checkpoint inhibitorsRebecca Karp Leaf, Jodi V Mones, Tushar Shenoy, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2025
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyGregory J Riely, Douglas E Wood, Billy W Loo, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in OncologyGregory J Riely, Douglas E Wood, David S Ettinger, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.Journal for Immunotherapy of Cancer|October 9, 2021
Acute kidney injury in patients treated with immune checkpoint inhibitorsShruti Gupta, Samuel A P Short, Meghan E Sise, et al.Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.Pageof 38